<DOC>
	<DOC>NCT00636168</DOC>
	<brief_summary>The purpose of the study is to determine if ipilimumab is effective in preventing or delaying recurrence and prolongs survival after complete resection of high risk stage III melanoma</brief_summary>
	<brief_title>Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Age â‰¥ 18 years Complete and adequate resection of Stage III melanoma with histologically confirmed melanoma metastatic to lymph node Diseasefree Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 Randomization within 12 weeks of surgery Prior therapy for melanoma except surgery Autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>